As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (US$123 Million)

Thursday, March 29, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

The GHIT Fund's new investments support work to accelerate schistosomiasis elimination; combat drug-resistant tuberculosis; deploy CRISPR gene-editing tools to fight Chagas disease; and develop a vaccine to stop malaria parasites from hijacking the human immune system

ID

Project Title

Collaboration Partners(Designated DevelopmentPartner is #1)

Disease

Intervention

Stage

Awarded Amount ?¥?

AwardedAmount ($)

Continuing

G2017-203

Preclinicaldevelopment and phase I activities on aselectedaminopyrazolecompound for visceralleishmaniasis

1. DNDi2. Takeda PharmaceuticalCompany Limited

Leishmaniasis

Drug

PreclinicalDevelopment,Clinical PhI

¥604,775,700

$5,636,307

G2014-208

G2017-211

Process Developmentand ClinicalManufacturing of anImmuno-focused,Mosquito-based Pan-malaria transmission-blocking vaccine:AnAPN1 v. 2.0.

1. University of Florida2. CellFree Sciences Co. Ltd.3. Ology Bioservices Inc.4. Hamamatsu Pharma Research(HPR)5. Infectious Disease ResearchInstitute (IDRI)6. Centre Pasteur du Cameroon(CPC)

Malaria

Vaccine

PreclinicalDevelopment

¥348,421,798

$3,247,174

G2015-214

G2017-101

Lead optimization ofnovel azetidine-basedtryptophan synthaseinhibitors as newmechanism of actiontreatment oftuberculosis

1. Broad Institute2. Eisai Co. Ltd.3. Colorado State University4. The University of Chicago5. TB Alliance

Tuberculosis

Drug

LeadOptimization

¥200,332,434

$1,867,031

New

H2017-101

HTL for selectivePlasmodiumproteasome inhibitorsas new potentresistance-reversingantimalarials

1. Medicines for MalariaVenture (MMV)2. The University of Melbourne'sBio21 Molecular Science andBiotechnology Institute3. Takeda Pharmaceutical Company Limited

Malaria

Drug

Hit-to-Lead

¥46,124,588

$429,866

T2015-134

H2017-102

New Hit-to-LeadActivity for New Anti-Malaria drugs betweenMMV and Sumitomo

1. Medicines for MalariaVenture (MMV)2. Sumitomo Dainippon PharmaCo., Ltd. (Sumitomo)

Malaria

Drug

Hit-to-Lead

¥44,550,000

$415,191

S2014-211

H2017-103

Neglected TropicalDiseases DrugDiscovery Booster III

1. DNDi – Drugs for NeglectedDiseases initiative2. Eisai Co. Ltd.3. Shionogi & Co., Ltd.4. Takeda PharmaceuticalCompany Ltd5. Astellas Pharma Inc.

Chagas disease,VL

Drug

Hit-to-Lead

¥149,832,868

$1,396,392

H2016-203

ID

Project Title

Collaboration Partners(Designated DevelopmentPartner is #1)

Disease

Intervention

Stage

Awarded Amount ?¥?

AwardedAmount ($)

Continuing

S2017-221

Chagas disease andLeishmaniasisScreening betweenDNDi and DaiichiSankyo Novare

1. DNDi2. Daiichi Sankyo RD Novare Co.,Ltd.

Chagas disease,VL

Drug

Hit Identification

¥11,900,000

$110,904

New

T2017-272

Novel diagnostics forschistosomiasiscontrol: developmentof defined antigens fordetection ofSchistosoma infection-specific antibodies inblood and urine

1. Lygature2. Institute of Tropical Medicine,Nagasaki University (NUITM)3. Department of Parasitology,Leiden University MedicalCenter (LUMC)

Schistosomiasis

Diagnostics

ConceptDevelopment

¥76,389,000

$711,920

New

T2017-274

Identification ofVaccine Targets thatWill Block theInteraction ofPlasmodiumfalciparum MalariaParasites with aComplementRegulator

1. The Pennsylvania State University2. Institute of Tropical Medicine,Nagasaki University3. Antigen Discovery, Inc.

Malaria

Vaccine

AntigenIdentification

¥88,190,035

$821,902

New

T2017-278

Target determinationand exploratoryresearch for discoveryof new drugs againstChagas disease

1. Nagasaki University(NEKKEN)2. National Institute of AdvancedIndustrial Science and Technology (AIST)3. High Energy AcceleratorResearch Organization (KEK)4. London School of Hygiene andTropical Medicine (LSHTM)

Chagas Disease

Drug

TargetIdentification

¥88,235,010

$822,321

New



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store